Mitragynine Pseudoindoxyl vs. 7-Hydroxymitragynine: Why This Comparison Matters
Kratom products have changed dramatically over the last several years. What was once mostly sold as crushed leaf, tea, or powder is now commonly marketed as concentrated extracts, shots, gummies, tablets, and “7-OH” products. These products may contain much higher levels of opioid-active compounds than traditional kratom leaf.
Two compounds that are especially important to understand are 7-hydroxymitragynine, often shortened to 7-OH, and mitragynine pseudoindoxyl. Both are related to kratom’s main alkaloid, mitragynine, but they are not the same thing. They differ in how they are formed, how they interact with opioid receptors, and why they may raise concern for dependence, withdrawal, and misuse.
For people already struggling with kratom use, 7-OH products, or other opioid-like substances, this distinction is not just chemistry. It can help explain why some newer kratom-related products feel stronger, cause more intense cravings, or lead to withdrawal symptoms that are difficult to manage without support.
What Is 7-Hydroxymitragynine?
7-hydroxymitragynine, or 7-OH, is a kratom-related alkaloid that acts on opioid receptors. It is found naturally in kratom in very small amounts, but some products are now marketed specifically for their 7-OH content. This matters because 7-OH is significantly more potent at opioid receptors than mitragynine, the primary alkaloid in the kratom plant. Research has identified 7-hydroxymitragynine as an active metabolite of mitragynine, meaning the body can convert mitragynine into 7-OH after use.
In practical terms, 7-OH is one of the reasons kratom can produce opioid-like effects, especially at higher doses or when concentrated extracts are used. These effects may include relaxation, pain relief, sedation, euphoria, nausea, constipation, tolerance, and withdrawal.
The FDA has also taken specific action around 7-OH products. In July 2025, the agency warned about products containing 7-hydroxymitragynine and recommended scheduling action for certain 7-OH products under the Controlled Substances Act.
What Is Mitragynine Pseudoindoxyl?
Mitragynine pseudoindoxyl is a chemical rearrangement product related to 7-hydroxymitragynine. It has received attention in research because it appears to have strong activity at opioid receptors, particularly the mu-opioid receptor, while also showing activity at delta-opioid receptors in some studies.
In a 2016 study, researchers described mitragynine pseudoindoxyl as a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist that produced potent pain-relieving effects in animal models. Another study found that 7-hydroxymitragynine can convert into mitragynine pseudoindoxyl in human plasma, raising questions about how kratom-related compounds behave differently in humans compared with some animal models.
That does not mean mitragynine pseudoindoxyl is a safe or approved medication. It means researchers are studying it because its pharmacology is complex. For the public, the more important takeaway is that kratom-related chemistry can involve multiple opioid-active compounds, some of which may be more potent than people realize.
Mitragynine Pseudoindoxyl vs. 7-Hydroxymitragynine
| Category | 7-Hydroxymitragynine | Mitragynine Pseudoindoxyl |
|---|---|---|
| Common name | 7-OH or 7-HMG | Mitragynine pseudoindoxyl |
| Relationship to kratom | A minor kratom alkaloid and active metabolite of mitragynine | A rearrangement product related to 7-OH |
| Opioid receptor activity | Potent opioid receptor activity, especially at mu-opioid receptors | Strong opioid receptor activity; studied as a mu-opioid agonist/delta-opioid antagonist |
| Product relevance | Increasingly found in concentrated commercial products marketed as 7-OH | More discussed in research and toxicology than typical retail labels |
| Main concern | Potency, dependence, withdrawal, misuse, and unclear product labeling | Potency, human metabolism questions, and opioid-like risk profile |
| Treatment relevance | People may develop opioid-like dependence and withdrawal from repeated use | May help explain why some kratom-related effects are stronger or more complex than expected |
The Simple Difference
The simplest way to understand the difference is this: For someone using kratom products, the label may mention kratom, mitragynine, extract strength, or 7-OH. It is much less likely to clearly explain how these compounds may convert, interact, or behave once inside the body.
That uncertainty is part of the problem. People may think they are using a “natural” or “plant-based” product without realizing they may be consuming concentrated opioid-active compounds.
Why 7-OH Products Are Especially Concerning
Traditional kratom leaf contains many alkaloids, with mitragynine usually being the most abundant. 7-OH, by contrast, is typically present in much smaller natural quantities. When products are concentrated, altered, or marketed specifically for 7-OH effects, the risk profile can change.
The FDA has described growing concern around novel products containing 7-hydroxymitragynine that are sold online and in smoke shops, gas stations, and convenience stores. These products may be marketed as wellness items, mood enhancers, pain relief alternatives, energy products, or relaxation aids.
For someone with a history of opioid addiction, kratom addiction, or substance use disorder, these products can be especially risky because they may activate some of the same reward and dependence pathways involved in opioid misuse.
Legal Loopholes and the Rise of New Psychoactive Compounds
Another reason 7-OH and related compounds matter is that they fit a pattern seen with other intoxicating substances: when one substance becomes restricted, banned, or heavily scrutinized, similar compounds may appear in the marketplace as a way to stay ahead of regulation.
A common comparison is delta-8 THC vs. delta-9 THC. Delta-9 THC is the main intoxicating compound in marijuana, while delta-8 THC is a chemically similar cannabinoid that became widely available after the 2018 Farm Bill created a federal hemp category based largely on delta-9 THC concentration. The FDA has warned that delta-8 THC products have not been evaluated or approved for safe use and may be marketed in ways that put public health at risk.
Something similar can happen with kratom-related products. As regulators focus more attention on kratom extracts, mitragynine, or 7-hydroxymitragynine, the market may shift toward related compounds, concentrated derivatives, altered formulations, or new product names that are harder for the average person to understand. The FDA has specifically warned consumers to avoid products containing added or enhanced levels of 7-OH, noting that while 7-OH occurs naturally in kratom in trace amounts, enhanced 7-OH products can be dangerous.
This does not mean every related compound is identical, and it does not mean the legal status is always the same from state to state. However, it does show why product marketing can move faster than public health guidance. A substance may be sold as “legal,” “natural,” “hemp-derived,” “kratom-derived,” or “not technically banned,” while still producing powerful effects on the brain and body.
For people in recovery or those with a history of opioid addiction, the risk is not only whether a product is legal. The bigger concern is whether it causes intoxication, cravings, tolerance, withdrawal, relapse risk, or compulsive use. Legal availability does not automatically mean a product is safe.
Are These Compounds Opioids?
This question can get confusing because kratom itself is often marketed as an herbal supplement, not as an opioid drug. However, several kratom-related compounds interact with opioid receptors. NIDA notes that kratom contains compounds including mitragynine and 7-hydroxymitragynine, and that people report using kratom for pain, mood, opioid withdrawal, and other reasons, while safety and effectiveness remain under study.
From a treatment perspective, the more useful question is not whether someone personally considers kratom an “opioid.” The more useful question is:
Is the product causing opioid-like effects, tolerance, cravings, withdrawal, or loss of control? If the answer is yes, the person may need professional help regardless of how the product is marketed.
Can 7-OH or Mitragynine Pseudoindoxyl Cause Dependence?
Repeated use of opioid-active substances can lead to tolerance and physical dependence. With kratom and 7-OH products, people may find that the same amount no longer works the way it used to. They may increase the dose, take it more often, switch to stronger extracts, or feel sick when they try to stop.
Common kratom or 7-OH withdrawal symptoms may include:
- Anxiety
- Irritability
- Insomnia
- Sweating
- Restless legs
- Muscle aches
- Nausea or stomach discomfort
- Diarrhea
- Runny nose or watery eyes
- Depression
- Strong cravings
- Fatigue
- Difficulty concentrating
Withdrawal can feel especially discouraging because many people begin using kratom products believing they are safer than opioids or easier to stop. Some people also use kratom to self-manage pain, anxiety, depression, or opioid withdrawal, which can make stopping more complicated.
Why Product Labels May Not Tell the Full Story
One of the biggest challenges with kratom-related products is that consumers may not know exactly what they are taking. A product may be labeled as kratom, mitragynine, 7-OH, enhanced kratom, extract, or a proprietary blend. The label may not clearly explain potency, conversion, contamination risk, serving size, or how the product could affect someone when mixed with alcohol, benzodiazepines, opioids, sleep medications, or other substances.
This is especially concerning with concentrated products. A person may assume a small tablet, shot, gummy, or beverage is mild because it looks like a supplement or energy product. In reality, concentrated products can expose the brain and body to much stronger opioid-like effects than traditional kratom leaf.
Mixing 7-OH, Kratom, or Other Substances
The risks can increase when kratom-related products are mixed with other substances. Combining opioid-active compounds with alcohol, benzodiazepines, sleep medications, gabapentin, muscle relaxers, or other sedating drugs may increase the risk of severe impairment, blackouts, accidents, or breathing problems.
This is one reason it is important to be honest with medical professionals about kratom, 7-OH, or other supplement use. Even if a product was bought legally, it can still affect treatment decisions, medication safety, withdrawal management, and overdose risk.
Signs Someone May Need Help for 7-OH or Kratom Use
A person may benefit from professional treatment if they:
- Use kratom, 7-OH, or extracts every day
- Feel sick, anxious, restless, or depressed without it
- Need higher doses to get the same effect
- Have tried to quit but keep going back
- Hide use from family or coworkers
- Spend more money than intended on products
- Use kratom or 7-OH to get through work, sleep, pain, or stress
- Mix it with alcohol, opioids, benzodiazepines, or other substances
- Experience cravings or panic when they run out
- Feel trapped by the cycle of use and withdrawal
Needing help does not mean someone is weak. It means the body and brain may have adapted to a substance that affects powerful reward and pain-regulation systems.
Treatment for Kratom, 7-OH, and Opioid-Like Dependence
Treatment should be based on the person’s symptoms, substance use history, mental health needs, medical risks, and withdrawal severity. Some people need medically monitored detox, while others may be appropriate for residential treatment or a structured outpatient plan.
At Brooks Healing Center, treatment may include support for:
- Kratom dependence
- 7-OH and Pseudoindoxyl misuse
- Opioid addiction
- Polysubstance use
- Anxiety, depression, trauma, and relapse triggers
- Withdrawal planning and relapse prevention
- Family education and long-term recovery support
Because kratom-related withdrawal can overlap with opioid withdrawal, it is important that treatment providers understand both the substance and the person’s full history. A safe plan should not focus only on stopping the product. It should also address why the person started using it, what withdrawal feels like, and what support they need to stay stable after detox.
Key Takeaways
7-hydroxymitragynine and mitragynine pseudoindoxyl are both kratom-related compounds with opioid receptor activity, but they are not identical. 7-OH is more commonly seen in consumer product discussions and newer retail products. Mitragynine pseudoindoxyl is a related compound that has been studied for its potent opioid receptor activity and may form from 7-OH under certain conditions in human plasma.
The most important point is not memorizing the chemistry. The most important point is recognizing the risk. If kratom, 7-OH, or extract products are causing cravings, withdrawal, dose escalation, or loss of control, professional treatment can help.
Get Help for Kratom or 7-OH Dependence
If you or someone you love is struggling with kratom, 7-hydroxymitragynine, extracts, or other opioid-like substances, Brooks Healing Center can help. Our team provides compassionate, structured addiction treatment designed to address withdrawal, cravings, mental health symptoms, and long-term recovery.
Call Brooks Healing Center today to speak with our admissions team and learn more about treatment options.
Frequently Asked Questions About Mitragynine Pseudoindoxyl vs. 7-Hydroxymitragynine
Is pseudoindoxyl stronger than 7-hydroxymitragynine?
Research suggests that mitragynine pseudoindoxyl may be more potent than 7-hydroxymitragynine at the mu-opioid receptor, which is one of the main receptor systems involved in opioid-like pain relief, euphoria, dependence, and withdrawal. One study noted that while 7-hydroxymitragynine is more potent than mitragynine, mitragynine pseudoindoxyl appears to be “yet more potent” than 7-hydroxymitragynine in certain receptor activity models.
However, “stronger” does not always mean the same thing in every context. Potency can vary depending on whether researchers are measuring receptor binding, pain-relieving effects, sedation, respiratory effects, or abuse potential. For readers, the practical takeaway is that both 7-OH and pseudoindoxyl are opioid-active kratom-related compounds that may carry serious risks when misused.
What is pseudo kratom, and how does it compare to 7-OH in kratom?
“Pseudo kratom” is not a precise medical or scientific term. People may use it informally to refer to mitragynine pseudoindoxyl, a kratom-related compound connected to 7-hydroxymitragynine chemistry. It is different from regular kratom leaf, which primarily contains mitragynine along with many other alkaloids.
7-OH, or 7-hydroxymitragynine, is more commonly discussed in consumer products and newer “enhanced kratom” or “7-OH” products. Mitragynine pseudoindoxyl is more commonly discussed in research because 7-hydroxymitragynine may convert into mitragynine pseudoindoxyl in human plasma.
In simple terms, 7-OH is the compound more likely to appear in product marketing, while pseudoindoxyl is a related opioid-active compound that helps explain why kratom chemistry can be more complex than product labels suggest.
Does Narcan work on 7-OH or pseudoindoxyl?
Narcan is the brand name for naloxone, a medication used to reverse opioid overdose. Because 7-OH and mitragynine pseudoindoxyl act on opioid receptors, naloxone may help in some cases of kratom-related opioid toxicity. A published case report described kratom ingestion requiring naloxone reversal, supporting the idea that naloxone can be clinically relevant when kratom produces opioid-like overdose symptoms.
That said, naloxone response can vary depending on the substance, dose, other drugs involved, timing, and the person’s condition. If someone is extremely sedated, hard to wake, breathing slowly, turning blue or gray, or suspected of overdosing after 7-OH, kratom, pseudoindoxyl, opioids, or any unknown substance, call 911 immediately and give naloxone if available. More than one dose may be needed, and medical evaluation is still necessary even if the person wakes up.
Are 7-OH and pseudoindoxyl addictive?
Yes, 7-OH can be addictive, especially when used repeatedly or in concentrated products. It has opioid-like activity and may contribute to tolerance, dependence, cravings, and withdrawal. NIDA notes that kratom contains active compounds including mitragynine and 7-hydroxymitragynine, and that kratom products are used for effects such as pain relief, mood changes, and opioid withdrawal self-management, while safety concerns remain under study.
Mitragynine pseudoindoxyl is less commonly encountered as a labeled consumer product, but it is also opioid-active. Some animal research has explored whether pseudoindoxyl may have a different abuse-liability profile than 7-OH, but that does not mean it is safe, non-addictive, or appropriate for self-use. From a treatment perspective, any kratom-related compound causing cravings, withdrawal, compulsive use, or loss of control should be taken seriously.
Are pseudoindoxyl and 7-OH opioids?
They are best described as opioid-active kratom-related compounds because they interact with opioid receptors. 7-hydroxymitragynine is known for potent mu-opioid receptor activity, and mitragynine pseudoindoxyl has been studied as a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist.
They are not the same as prescription opioids like oxycodone or illicit opioids like heroin or fentanyl, but they can produce opioid-like effects. This matters because opioid receptor activity can be linked to pain relief, euphoria, sedation, tolerance, dependence, withdrawal, and overdose risk.
What’s the difference between 7-OH and pseudoindoxyl?
7-OH, short for 7-hydroxymitragynine, is a kratom-related alkaloid and active metabolite of mitragynine. It is more commonly discussed in relation to kratom extracts, 7-OH tablets, shots, gummies, and other concentrated consumer products.
Mitragynine pseudoindoxyl is a related compound that can form from 7-hydroxymitragynine under certain conditions, including in human plasma. It has been studied for potent opioid receptor activity and may be even more potent than 7-OH in some receptor models.
The simple difference is this: 7-OH is the better-known compound showing up in product discussions, while pseudoindoxyl is a related research compound that may help explain some of the powerful opioid-like effects connected to kratom chemistry.
Sources
- Kamble, S. H., Berthold, E. C., King, T. I., Raju Kanumuri, S. R., Popa, R., Herting, J. R., León, F., Sharma, A., McCurdy, C. R., & Avery, B. A. (2020). Metabolism of a kratom alkaloid metabolite in human plasma increases its opioid potency and efficacy. ACS Pharmacology & Translational Science, 3(6), 1063–1068. https://pmc.ncbi.nlm.nih.gov/articles/PMC7737207/
- Váradi, A., Marrone, G. F., Palmer, T. C., Narayan, A., Szabó, M. R., Le Rouzic, V., Grinnell, S. G., Subrath, J. J., Warner, E., Kalra, S., Hunkele, A., Pagirsky, J., Eans, S. O., Medina, J. M., Xu, J., Pan, Y.-X., Borics, A., Pasternak, G. W., McLaughlin, J. P., & Majumdar, S. (2016). Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-arrestin-2. Journal of Medicinal Chemistry, 59(18), 8381–8397. https://pmc.ncbi.nlm.nih.gov/articles/PMC5344672/
- Kruegel, A. C., Uprety, R., Grinnell, S. G., Langreck, C., Pekarskaya, E. A., Le Rouzic, V., Ansonoff, M., Gassaway, M. M., Pintar, J. E., Pasternak, G. W., Javitch, J. A., & Majumdar, S. (2019). 7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. ACS Central Science, 5(6), 992–1001. https://pmc.ncbi.nlm.nih.gov/articles/PMC6598159/
- Obeng, S., Wilkerson, J. L., León, F., Reeves, M. E., Restrepo, L. F., Gamez-Jimenez, L. R., Patel, A., Behnke, M., Chear, N. J. Y., Ramanathan, S., Sharma, A., Fantegrossi, W. E., McMahon, L. R., McCurdy, C. R., & McLaughlin, J. P. (2021). In vitro affinity and efficacy for μ-opioid receptor and opioid-like behavioral effects of mitragynine and 7-hydroxymitragynine in rats. Journal of Pharmacology and Experimental Therapeutics, 376(3), 410–427. https://pmc.ncbi.nlm.nih.gov/articles/PMC7923387/
- U.S. Food and Drug Administration. (2022, May 4). 5 things to know about delta-8 tetrahydrocannabinol — delta-8 THC. https://www.fda.gov/consumers/consumer-updates/5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc
